Andrew Bourgoin > Biography
Biography Information
Andrew Fischer Bourgoin is a Senior Pharmaceutical Research Analyst - Biologcs at Thomson Reuters (TR), the world’s leading information provider and global media company. In this role, Andrew is responsible for collecting and validating the intelligence contained in the Newport product suite that focuses on developments within the global biologic pharmaceutical landscape.
Since joining Thomson Reuters, Andrew has generated numerouos offerings in the field of biosimilar thought leadership. In January of 2011, Andrew authored a Thomson Reuters White Paper regarding follow-on biologic development title What you need to know about the US follow-on biologic market: Implications, Strategies and Impacts. Andrew’s work on the topic of biosimilars also includes articles published in Pharma Magazine and CHEManager, and a presentation at the 2012 New York Pharma Forum on Biosimilars. . Additionally Andrew has given multiple webinars on the topic of global biologic competition through Thomson Reuters and Informex.
Andrew received a M.P.P. in Public Management from the Muskie School of Public Service and a B.A. from the University of Nebraska.
Since joining Thomson Reuters, Andrew has generated numerouos offerings in the field of biosimilar thought leadership. In January of 2011, Andrew authored a Thomson Reuters White Paper regarding follow-on biologic development title What you need to know about the US follow-on biologic market: Implications, Strategies and Impacts. Andrew’s work on the topic of biosimilars also includes articles published in Pharma Magazine and CHEManager, and a presentation at the 2012 New York Pharma Forum on Biosimilars. . Additionally Andrew has given multiple webinars on the topic of global biologic competition through Thomson Reuters and Informex.
Andrew received a M.P.P. in Public Management from the Muskie School of Public Service and a B.A. from the University of Nebraska.